Different embryo-fetal toxicity effects for three VLA-4 antagonists

F Crofts1, M Pino, B DeLise

  • 1Department of Drug Safety Evaluation, Aventis Inc., Bridgewater, New Jersey 08807, USA. Frances.Crofts@aventis.com

Abstract

Insights

The VLA-4 antagonist IVL984 demonstrated potent teratogenicity, causing embryo lethality and cardiac malformations, including spiral septal defects, in multiple species. In contrast, IVL745 showed no teratogenic effects, and HMR1031 caused only slight embryo-fetal effects at maternally toxic doses.

Area of Science:

  • Developmental toxicology
  • Pharmacology
  • Immunology

Background:

  • Very late antigen 4 (VLA-4) is crucial for cell-cell interactions during development.
  • Genetic deficiencies in VLA-4 or its ligand VCAM-1 lead to embryonic lethality due to abnormal development.
  • Understanding VLA-4 antagonist teratogenicity is vital for drug safety.

Purpose of the Study:

  • To evaluate and compare the teratogenic potential of three VLA-4 antagonists: IVL745, HMR1031, and IVL984.
  • To identify dose-dependent effects and specific malformations induced by these compounds.
  • To assess the safety profile of VLA-4 antagonists during embryonic development.

Main Methods:

  • Standard embryo-fetal developmental toxicity studies were conducted in rats and rabbits via subcutaneous administration.
  • IVL984 was also tested in mice.
  • Fetuses underwent external, visceral, and skeletal examinations to identify developmental abnormalities.

Main Results:

  • IVL745 exhibited no significant maternal or fetal toxicity at tested doses.
  • HMR1031 caused maternal toxicity and slight fetal effects (e.g., reduced body weight, sternebral defects) at high doses.
  • IVL984 was a potent teratogen, inducing embryo lethality, cardiac malformations (including spiral septal defects), and skeletal defects at low doses, with minimal maternal toxicity except for abortions in rabbits.

Conclusions:

  • IVL745 is not teratogenic.
  • HMR1031 demonstrates mild embryo-fetal toxicity at maternally toxic doses.
  • IVL984 is a potent teratogen, causing significant developmental abnormalities, including cardiac malformations and embryo lethality, across multiple species at non-maternally toxic doses.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...